share_log

Aurinia Pharmaceuticals Analyst Ratings

Aurinia Pharmaceuticals Analyst Ratings

奧里尼亞製藥分析師評級
Benzinga ·  2023/09/22 06:18
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/22/2023 81.38% HC Wainwright & Co. → $15 Reiterates Buy → Buy
08/07/2023 81.38% HC Wainwright & Co. $14 → $15 Maintains Buy
07/06/2023 81.38% Cantor Fitzgerald → $15 Reiterates Overweight → Overweight
05/03/2023 69.29% HC Wainwright & Co. → $14 Reiterates → Buy
02/23/2023 33.01% RBC Capital → $11 Reiterates → Outperform
01/04/2023 33.01% RBC Capital $10 → $11 Maintains Outperform
11/07/2022 69.29% HC Wainwright & Co. $26 → $14 Maintains Buy
11/04/2022 20.92% RBC Capital $18 → $10 Maintains Outperform
11/04/2022 — Oppenheimer Downgrades Outperform → Perform
11/04/2022 45.1% SVB Leerink $17 → $12 Maintains Outperform
08/09/2022 214.39% HC Wainwright & Co. $30 → $26 Maintains Buy
08/08/2022 57.19% Oppenheimer $15 → $13 Maintains Outperform
05/05/2022 202.3% Cantor Fitzgerald → $25 Assumes → Overweight
05/05/2022 262.76% HC Wainwright & Co. $33 → $30 Maintains Buy
04/28/2022 166.02% RBC Capital $27 → $22 Maintains Outperform
03/08/2022 166.02% SVB Leerink $30 → $22 Maintains Outperform
03/01/2022 226.48% RBC Capital $31 → $27 Maintains Outperform
02/23/2022 274.85% RBC Capital $34 → $31 Maintains Outperform
12/10/2021 274.85% Oppenheimer $33 → $31 Upgrades Perform → Outperform
11/04/2021 299.03% Oppenheimer $32 → $33 Maintains Perform
11/04/2021 383.68% HC Wainwright & Co. $35 → $40 Maintains Buy
11/04/2021 323.22% SVB Leerink $28 → $35 Maintains Outperform
10/28/2021 286.94% Oppenheimer $28 → $32 Downgrades Outperform → Perform
10/26/2021 311.12% RBC Capital $23 → $34 Maintains Outperform
01/27/2021 238.57% SVB Leerink $24 → $28 Maintains Outperform
01/25/2021 323.22% HC Wainwright & Co. $30 → $35 Maintains Buy
11/03/2020 238.57% HC Wainwright & Co. $34 → $28 Maintains Buy
08/12/2020 311.12% HC Wainwright & Co. $33 → $34 Maintains Buy
07/22/2020 299.03% HC Wainwright & Co. $32 → $33 Maintains Buy
03/06/2020 286.94% Cantor Fitzgerald $30 → $32 Maintains Overweight
12/16/2019 286.94% HC Wainwright & Co. $25 → $32 Maintains Buy
09/10/2019 69.29% Oppenheimer → $14 Initiates Coverage On → Outperform
03/20/2019 33.01% Raymond James $9 → $11 Maintains Outperform
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
09/22/2023 81.38% HC Wainwright公司 →$15 重申 購買→購買
08/07/2023 81.38% HC Wainwright公司 $14→$15 維護 買
07/06/2023 81.38% 康託·菲茨傑拉德 →$15 重申 超重→超重
05/03/2023 69.29% HC Wainwright公司 →$14 重申 →購買
02/23/2023 33.01% 加拿大皇家銀行資本 →$11 重申 →跑贏大盤
01/04/2023 33.01% 加拿大皇家銀行資本 $10→$11 維護 跑贏大盤
11/07/2022 69.29% HC Wainwright公司 $26→$14 維護 買
11/04/2022 20.92% 加拿大皇家銀行資本 $18→$10 維護 跑贏大盤
11/04/2022 - 奧本海默 評級下調 超越→表現
11/04/2022 45.1% SVB Leerink $17→$12 維護 跑贏大盤
08/09/2022 214.39% HC Wainwright公司 $30→$26 維護 買
2022/08/08 57.19% 奧本海默 $15→$13 維護 跑贏大盤
05/05/2022 202.3% 康託·菲茨傑拉德 →$25 假設 →超重
05/05/2022 262.76% HC Wainwright公司 $33→$30 維護 買
04/28/2022 166.02% 加拿大皇家銀行資本 $27→$22 維護 跑贏大盤
03/08/2022 166.02% SVB Leerink $30→$22 維護 跑贏大盤
03/01/2022 226.48% 加拿大皇家銀行資本 $31→$27 維護 跑贏大盤
02/23/2022 274.85% 加拿大皇家銀行資本 $34→$31 維護 跑贏大盤
2021年12月10日 274.85% 奧本海默 $33→$31 升級 →表現強於大盤
11/04/2021 299.03% 奧本海默 $32→$33 維護 執行
11/04/2021 383.68% HC Wainwright公司 $35→$40 維護 買
11/04/2021 323.22% SVB Leerink $28→$35 維護 跑贏大盤
10/28/2021 286.94% 奧本海默 $28→$32 評級下調 超越→表現
10/26/2021 311.12% 加拿大皇家銀行資本 $23→$34 維護 跑贏大盤
2021/01/27 238.57% SVB Leerink $24→$28 維護 跑贏大盤
2021/01/25 323.22% HC Wainwright公司 $30→$35 維護 買
11/03/2020 238.57% HC Wainwright公司 $34→$28 維護 買
2020年08月12日 311.12% HC Wainwright公司 $33→$34 維護 買
07/22/2020 299.03% HC Wainwright公司 $32→$33 維護 買
03/06/2020 286.94% 康託·菲茨傑拉德 $30→$32 維護 超重
2019年12月16日 286.94% HC Wainwright公司 $25→$32 維護 買
2019年09月10日 69.29% 奧本海默 →$14 開始承保 →跑贏大盤
2019/03/20 33.01% 雷蒙德·詹姆斯 $9→$11 維護 跑贏大盤

What is the target price for Aurinia Pharmaceuticals (AUPH)?

金色製藥(AUPH)的目標價是多少？

The latest price target for Aurinia Pharmaceuticals (NASDAQ: AUPH) was reported by HC Wainwright & Co. on September 22, 2023. The analyst firm set a price target for $15.00 expecting AUPH to rise to within 12 months (a possible 81.38% upside). 10 analyst firms have reported ratings in the last year.

金色製藥(納斯達克代碼：AUPH)的最新目標價是由HC Wainwright&Co.於2023年9月22日報道的。這家分析公司將目標價定為15.00美元，預計AUPH將在12個月內上漲至81.38%。去年有10家分析公司公佈了評級。

What is the most recent analyst rating for Aurinia Pharmaceuticals (AUPH)?

金色製藥(AUPH)最近的分析師評級是多少？

The latest analyst rating for Aurinia Pharmaceuticals (NASDAQ: AUPH) was provided by HC Wainwright & Co., and Aurinia Pharmaceuticals reiterated their buy rating.

納斯達克(Sequoia PharmPharmticals)(股票代碼：AUPH)的最新分析師評級由HC Wainwright&Co.提供，Auinia PharmPharmticals重申其買入評級。

When is the next analyst rating going to be posted or updated for Aurinia Pharmaceuticals (AUPH)?

金色製藥(AUPH)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aurinia Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aurinia Pharmaceuticals was filed on September 22, 2023 so you should expect the next rating to be made available sometime around September 22, 2024.

分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與aurinia PharmPharmticals的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。金色製藥的上一次評級是在2023年9月22日提交的，所以你應該預計下一次評級將在2024年9月22日左右的某個時候公佈。

Is the Analyst Rating Aurinia Pharmaceuticals (AUPH) correct?

分析師對金色製藥(AUPH)的評級正確嗎？

While ratings are subjective and will change, the latest Aurinia Pharmaceuticals (AUPH) rating was a reiterated with a price target of $0.00 to $15.00. The current price Aurinia Pharmaceuticals (AUPH) is trading at is $8.27, which is within the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的金色製藥(AUPH)評級被重申，目標價在0.00美元至15.00美元之間。目前金色製藥(AUPH)的交易價格為8.27美元，在分析師的預測範圍內。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論